Skip to main content
Top
Published in: Osteoporosis International 1/2011

Open Access 01-01-2011 | Review

Oral bisphosphonate compliance and persistence: a matter of choice?

Authors: S. L. Silverman, J. T. Schousboe, D. T. Gold

Published in: Osteoporosis International | Issue 1/2011

Login to get access

Abstract

Compliance to oral bisphosphonates is suboptimal, with negative consequences of increased healthcare utilization and less effective fracture risk reduction. Extending dose interval increased adherence only moderately. We used literature derived from multiple chronic conditions to examine the problem of noncompliance with osteoporosis medication. We reviewed the literature on adherence to osteoporosis medication as well as that across multiple chronic conditions to understand what is known about the cause of the poor adherence. Poor compliance to oral medications is due mostly, not to forgetfulness, but to deliberate choice. Gender differences and style of healthcare management also play a role. Preliminary data suggest psychobehavioral interventions may help to improve motivation. We need to understand better reasons for poor compliance before effective interventions can be developed. Forgetfulness is only a small part of poor compliance. Patient preferences must be considered in medication decision making.
Literature
1.
go back to reference Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031CrossRefPubMed Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031CrossRefPubMed
2.
go back to reference Silverman SL, Cramer JA, Sunyecz JA, et al (2007) Women are more persistent with monthly bisphosphonate therapy compared to weekly bisphosphonates: 12 month results from two retrospective databases. Presented at ASBMR Montreal, 19 Sept 2007. Abstract W366 Silverman SL, Cramer JA, Sunyecz JA, et al (2007) Women are more persistent with monthly bisphosphonate therapy compared to weekly bisphosphonates: 12 month results from two retrospective databases. Presented at ASBMR Montreal, 19 Sept 2007. Abstract W366
3.
go back to reference Cotte FE, Fardelione P, Mercier F, Gaudin AF, Roux C (2009) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 29(1):125–139 Cotte FE, Fardelione P, Mercier F, Gaudin AF, Roux C (2009) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 29(1):125–139
4.
go back to reference Gold DT, Safi W, Trinh H (2006) Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 22(12):2383–2391CrossRefPubMed Gold DT, Safi W, Trinh H (2006) Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 22(12):2383–2391CrossRefPubMed
5.
go back to reference Gorai I, Tanaka Y, Hattori S, Iwaoki Y (2010) Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene or alfacalcidol in postmenopausal Japanese women. J Bone Miner Metab 28:176–184CrossRefPubMed Gorai I, Tanaka Y, Hattori S, Iwaoki Y (2010) Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene or alfacalcidol in postmenopausal Japanese women. J Bone Miner Metab 28:176–184CrossRefPubMed
6.
go back to reference Arden NK, Earl S, Fisher DJ et al (2006) Persistence with teriparitide in patients with osteoporosis: the UK experience. Osteoporos Int 17:1626–1629CrossRefPubMed Arden NK, Earl S, Fisher DJ et al (2006) Persistence with teriparitide in patients with osteoporosis: the UK experience. Osteoporos Int 17:1626–1629CrossRefPubMed
7.
go back to reference Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M (2008) Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 336(7653):1114–1117CrossRefPubMed Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M (2008) Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 336(7653):1114–1117CrossRefPubMed
8.
go back to reference Jackevicius CA, Mamdani M, Tu JV (2002) Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288:462–467CrossRefPubMed Jackevicius CA, Mamdani M, Tu JV (2002) Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288:462–467CrossRefPubMed
10.
go back to reference Reginster JY (2006) Adherence and persistence: impact and outcomes and health care resources. Bone 38(2 Suppl 2):S18–S21CrossRefPubMed Reginster JY (2006) Adherence and persistence: impact and outcomes and health care resources. Bone 38(2 Suppl 2):S18–S21CrossRefPubMed
11.
go back to reference Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968CrossRefPubMed Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968CrossRefPubMed
12.
go back to reference Weycker D, Macarios D, Edelsberg J, Oster G (2007) Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 18:271–277CrossRefPubMed Weycker D, Macarios D, Edelsberg J, Oster G (2007) Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 18:271–277CrossRefPubMed
13.
go back to reference Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928CrossRefPubMed Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928CrossRefPubMed
14.
go back to reference Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818CrossRefPubMed Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818CrossRefPubMed
15.
go back to reference Caro JJ, Ishak KJ, Kf H, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapies on fracture rates in actual practice. Osteoporos Int 15:1003–1008CrossRefPubMed Caro JJ, Ishak KJ, Kf H, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapies on fracture rates in actual practice. Osteoporos Int 15:1003–1008CrossRefPubMed
16.
go back to reference McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the prevention and treatment of osteoporosis. Maturitas 48:271–287CrossRefPubMed McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the prevention and treatment of osteoporosis. Maturitas 48:271–287CrossRefPubMed
17.
go back to reference Siris ES, Harris ST, Cj R, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022CrossRefPubMed Siris ES, Harris ST, Cj R, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022CrossRefPubMed
18.
go back to reference Curtis JR, Westfall AO, Cheng H, Lyles k, Saag K, Delzell E (2008) Benefit of adherence with bisphosphonates depends on the age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 23:1435–1441CrossRefPubMed Curtis JR, Westfall AO, Cheng H, Lyles k, Saag K, Delzell E (2008) Benefit of adherence with bisphosphonates depends on the age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 23:1435–1441CrossRefPubMed
19.
go back to reference Feldstein A (2009) Effectiveness of bisphosphonate therapy in a community setting. Bone 44:153–159CrossRefPubMed Feldstein A (2009) Effectiveness of bisphosphonate therapy in a community setting. Bone 44:153–159CrossRefPubMed
20.
go back to reference Silverman SL, Gold DT (2008) Compliance and persistence with osteoporosis therapies. Curr Rheumatol Rep 10(2):118–122CrossRefPubMed Silverman SL, Gold DT (2008) Compliance and persistence with osteoporosis therapies. Curr Rheumatol Rep 10(2):118–122CrossRefPubMed
21.
go back to reference Cline RR, Farley JF, Hansen RA, Schommer JC (2005) Osteoporosis beliefs and antiresorptive medication use. Maturitas 50:196–208CrossRefPubMed Cline RR, Farley JF, Hansen RA, Schommer JC (2005) Osteoporosis beliefs and antiresorptive medication use. Maturitas 50:196–208CrossRefPubMed
22.
go back to reference McHorney CA, Schousboe JT, Cline RR, Weiss TW (2007) The impact of osteoporosis medication beliefs and side effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin 23:3137–3152CrossRefPubMed McHorney CA, Schousboe JT, Cline RR, Weiss TW (2007) The impact of osteoporosis medication beliefs and side effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin 23:3137–3152CrossRefPubMed
23.
go back to reference Liel Y, Castel H, Bonneh DY (2003) Impact of subsidizing effective anti-osteoporosis drugs on compliance with management guidelines in patients following low impact fractures. Osteoporos Int 14:490–495CrossRefPubMed Liel Y, Castel H, Bonneh DY (2003) Impact of subsidizing effective anti-osteoporosis drugs on compliance with management guidelines in patients following low impact fractures. Osteoporos Int 14:490–495CrossRefPubMed
24.
go back to reference de Bekker-Grob EW, Essink-Bot ML, Meerding WJ, Pols HAP, Koes BW, Steyerberg EW (2008) Patients’ preferences for osteoporosis drug treatment: a discrete choice experiment. Osteoporos Int 19:1029–1037CrossRefPubMed de Bekker-Grob EW, Essink-Bot ML, Meerding WJ, Pols HAP, Koes BW, Steyerberg EW (2008) Patients’ preferences for osteoporosis drug treatment: a discrete choice experiment. Osteoporos Int 19:1029–1037CrossRefPubMed
25.
go back to reference Fraenkel L, Constantinescu F, Oberto Medina M, Wittink DR (2006) Womens preferences for prevention of bone loss. J Rheumatol 32:1086–1092 Fraenkel L, Constantinescu F, Oberto Medina M, Wittink DR (2006) Womens preferences for prevention of bone loss. J Rheumatol 32:1086–1092
26.
go back to reference Karter AJ, Parker MM, Moffet HH, Ahmed AT, Ja S, Selby JV (2009) New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res 44:1445–1448CrossRef Karter AJ, Parker MM, Moffet HH, Ahmed AT, Ja S, Selby JV (2009) New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res 44:1445–1448CrossRef
27.
go back to reference Schwarzer R, Fuchs R (1995) Self-efficacy and health behaviors. In: Connor M, Norman P (eds) Predicting health behavior. Open University Press, Philadelphia, pp 163–196 Schwarzer R, Fuchs R (1995) Self-efficacy and health behaviors. In: Connor M, Norman P (eds) Predicting health behavior. Open University Press, Philadelphia, pp 163–196
28.
go back to reference Carnevale V, Nieddu L, Romagnoli E, Bona E, Piemonte S, Scillitani A, Minisola S (2006) Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian study. Osteoporos Int 17:478–483CrossRefPubMed Carnevale V, Nieddu L, Romagnoli E, Bona E, Piemonte S, Scillitani A, Minisola S (2006) Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian study. Osteoporos Int 17:478–483CrossRefPubMed
29.
go back to reference Donovan JL (1995) Patient decision making. The missing ingredient in compliance research. Int J Technol Assess Health Care 11(3):443–455CrossRefPubMed Donovan JL (1995) Patient decision making. The missing ingredient in compliance research. Int J Technol Assess Health Care 11(3):443–455CrossRefPubMed
30.
go back to reference International Osteoporosis Foundation (2005) The adherence gap: why osteoporosis patients don’t continue with treatment. Nyon, Switzerland International Osteoporosis Foundation (2005) The adherence gap: why osteoporosis patients don’t continue with treatment. Nyon, Switzerland
31.
go back to reference Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123CrossRefPubMed Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123CrossRefPubMed
32.
go back to reference Delmas PD, Vrijens B, Eastell R, Roux C, Pois HA, Ringe JD, Grauer A, Cahall D, Watts NB, Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296–1304CrossRefPubMed Delmas PD, Vrijens B, Eastell R, Roux C, Pois HA, Ringe JD, Grauer A, Cahall D, Watts NB, Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296–1304CrossRefPubMed
33.
go back to reference Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev 16(2):CD000011 Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev 16(2):CD000011
34.
go back to reference Gleeson T, Iversen MD, Avorn J, Brookhart AM, Katz JN, Losina E, May F, Patrick AR, Shrank WH, Solomon DH (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int. doi:10.1007/s00198-009-0976-0 Gleeson T, Iversen MD, Avorn J, Brookhart AM, Katz JN, Losina E, May F, Patrick AR, Shrank WH, Solomon DH (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int. doi:10.​1007/​s00198-009-0976-0
35.
go back to reference Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 10:348–354CrossRef Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 10:348–354CrossRef
36.
go back to reference Curtis JR, Xi J, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E (2009) Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care 47:334–341CrossRefPubMed Curtis JR, Xi J, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E (2009) Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care 47:334–341CrossRefPubMed
37.
go back to reference Schneider PJ, Murphy JE, Pedersen CA (2003) Impact of medication packaging on adherence and treatment outcomes in older ambulatory patients. J Am Pharm Assoc 48:58–63CrossRef Schneider PJ, Murphy JE, Pedersen CA (2003) Impact of medication packaging on adherence and treatment outcomes in older ambulatory patients. J Am Pharm Assoc 48:58–63CrossRef
38.
go back to reference Cocosila M, Archer N, Haynes RB, Yuan Y (2009) Can wireless text messaging improve adherence to preventive activities? Results of a randomized controlled trial. Int J Med Inform 78:230–238CrossRefPubMed Cocosila M, Archer N, Haynes RB, Yuan Y (2009) Can wireless text messaging improve adherence to preventive activities? Results of a randomized controlled trial. Int J Med Inform 78:230–238CrossRefPubMed
39.
go back to reference Hayes TL, Cobbinah K, Dishongh T, Kaye JA, Kimel J, Labhard M, Leen T, Lundell J, Ozertem U, Pvael M, Phillipose M, Rhodes K, Vurgun S (2009) A study of medication taking and unobtrusive, intelligent reminding. Telemed J E Health 15:770–776CrossRefPubMed Hayes TL, Cobbinah K, Dishongh T, Kaye JA, Kimel J, Labhard M, Leen T, Lundell J, Ozertem U, Pvael M, Phillipose M, Rhodes K, Vurgun S (2009) A study of medication taking and unobtrusive, intelligent reminding. Telemed J E Health 15:770–776CrossRefPubMed
40.
go back to reference Young RJ, Taylor J, Friede T, Hollis S, Mason JM, Lee P, Burns E, Long AF, Gambling T, New JP, Gibson JM (2005) Pro-active call center treatment support (PACCTS) to improve glucose control in type 2 diabetes: a randomized controlled trial. Diabetes Care 28:278–282CrossRefPubMed Young RJ, Taylor J, Friede T, Hollis S, Mason JM, Lee P, Burns E, Long AF, Gambling T, New JP, Gibson JM (2005) Pro-active call center treatment support (PACCTS) to improve glucose control in type 2 diabetes: a randomized controlled trial. Diabetes Care 28:278–282CrossRefPubMed
41.
go back to reference Warriner AH, Curtis JR (2009) Adherence to osteoporosis treatments: room for improvement. Curr Opin Rheumatol 21:356–362CrossRefPubMed Warriner AH, Curtis JR (2009) Adherence to osteoporosis treatments: room for improvement. Curr Opin Rheumatol 21:356–362CrossRefPubMed
42.
go back to reference Cooper A, Drake J, Brankin E, PERSIST Investigators (2006) Treatment persistence withonce-monthly ibandronate and patient support vs once weekly alendronate: results from the PERSIST trial. Int J Clin Pract 60:896–905CrossRefPubMed Cooper A, Drake J, Brankin E, PERSIST Investigators (2006) Treatment persistence withonce-monthly ibandronate and patient support vs once weekly alendronate: results from the PERSIST trial. Int J Clin Pract 60:896–905CrossRefPubMed
43.
go back to reference Miller WR, Rollnick S (2002) Motivational interviewing: preparing people for change. Guilford Press, New York Miller WR, Rollnick S (2002) Motivational interviewing: preparing people for change. Guilford Press, New York
44.
go back to reference Swanson AJ, Pantalon MV, Cohen KR (1999) Motivational interviewing and treatment adherence among psychiatric and dually diagnosed patients. J Nerv Ment Disease 187:630–635CrossRef Swanson AJ, Pantalon MV, Cohen KR (1999) Motivational interviewing and treatment adherence among psychiatric and dually diagnosed patients. J Nerv Ment Disease 187:630–635CrossRef
45.
go back to reference Cotte FE, Fautrel B, Pouvourville G De (2009) A Markov model simulation of the effect of treatment persistence in postmenopausal osteoporosis. Med Decis Making 29:125–139CrossRefPubMed Cotte FE, Fautrel B, Pouvourville G De (2009) A Markov model simulation of the effect of treatment persistence in postmenopausal osteoporosis. Med Decis Making 29:125–139CrossRefPubMed
Metadata
Title
Oral bisphosphonate compliance and persistence: a matter of choice?
Authors
S. L. Silverman
J. T. Schousboe
D. T. Gold
Publication date
01-01-2011
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 1/2011
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-010-1274-6

Other articles of this Issue 1/2011

Osteoporosis International 1/2011 Go to the issue